N2OFF shares surge 49.70% premarket as MitoCareX Bio reports positive in vitro anti-inflammatory data in human immune cells.
ByAinvest
Thursday, Jan 22, 2026 8:12 am ET1min read
NITO--
N2OFF Inc. surged 49.70% in premarket trading following the announcement that its subsidiary MitoCareX Bio reported preliminary in vitro data showing selected small-molecule candidates reduced pro-inflammatory markers in human immune cells. The MITOLINE™ platform’s ability to model mitochondrial carriers and identify anti-inflammatory compounds positions the company to target a market projected to exceed $120 billion by 2030. These results validate mitochondrial carrier modulation as a therapeutic strategy for inflammatory metabolic diseases, accelerating pre-clinical plans and attracting investor optimism about commercial potential.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet